Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (31-40 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|August 18, 2020
Publisher Correction: Histone-writer cancer drugs enter center stageKen Garber
Nature Biotechnology|July 10, 2020
Coronavirus vaccine developers wary of errant antibodiesKen Garber
Journal of the National Cancer Institute|January 17, 2002
Could less be more? Low-dose chemotherapy goes on trialKen Garber
Journal of the National Cancer Institute|June 6, 2002
Silence of the genes: cancer epigenetics arrivesKen Garber
Journal of the National Cancer Institute|June 5, 2003
Why it hurts: researchers seek mechanisms of cancer painKen Garber
Journal of the National Cancer Institute|June 8, 2012
At loose ends: telomere theories of aging and cancer begin to convergeKen Garber
Journal of the National Cancer Institute|April 26, 2011
Inducing indigestion: companies embrace autophagy inhibitorsKen Garber
Journal of the National Cancer Institute|November 26, 2014
Promising early results for immunotherapy-antiangiogenesis combinationKen Garber
Journal of the National Cancer Institute|July 21, 2005
New checkpoint blockers begin human trialsKen Garber
Nature Biotechnology|April 9, 2005
Peptide leads new class of chronic pain drugsKen Garber
Pageof 20

Showing results (31-40 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|August 18, 2020
Publisher Correction: Histone-writer cancer drugs enter center stageKen Garber
Nature Biotechnology|July 10, 2020
Coronavirus vaccine developers wary of errant antibodiesKen Garber
Journal of the National Cancer Institute|January 17, 2002
Could less be more? Low-dose chemotherapy goes on trialKen Garber
Journal of the National Cancer Institute|June 6, 2002
Silence of the genes: cancer epigenetics arrivesKen Garber
Journal of the National Cancer Institute|June 5, 2003
Why it hurts: researchers seek mechanisms of cancer painKen Garber
Journal of the National Cancer Institute|June 8, 2012
At loose ends: telomere theories of aging and cancer begin to convergeKen Garber
Journal of the National Cancer Institute|April 26, 2011
Inducing indigestion: companies embrace autophagy inhibitorsKen Garber
Journal of the National Cancer Institute|November 26, 2014
Promising early results for immunotherapy-antiangiogenesis combinationKen Garber
Journal of the National Cancer Institute|July 21, 2005
New checkpoint blockers begin human trialsKen Garber
Nature Biotechnology|April 9, 2005
Peptide leads new class of chronic pain drugsKen Garber
Pageof 20